       Document 0038
 DOCN  M9630038
 TI    [The problem of the interferon therapy of patients with chronic viral
       hepatitis]
 DT    9603
 AU    Kokoreva LN; Zmyzgova AV; Shalygina NB
 SO    Zh Mikrobiol Epidemiol Immunobiol. 1995 Sep-Oct;(5):101-4. Unique
       Identifier : AIDSLINE MED/96093404
 AB    In this work the results of the clinico-immunological evaluation of the
       therapeutic effectiveness of alpha-interferon preparations are presented
       and criteria suitable for use in screening patients with chronic virus
       hepatitis, sensitive to interferon therapy, are discussed. The study
       revealed that the use of alpha-interferon preparations in single doses
       of 1-3 x 10(6) in a prolonged course of treatment (6-12 months)
       facilitated essential improvement in the clinical course of the disease
       and ensures correction of the immune status in 55.6% of patients with
       chronic active hepatitis (CAH) resulting in cirrhosis of the liver and
       57.9% of patients with CAH moderate activity. Indications for the use of
       alpha-interferon preparations in patients with CAH-induced cirrhosis
       were high activity of the cytolytic process, the presence of
       immunodeficiency, faintly pronounced autoimmune process and the presence
       of protein shifts.
 DE    Adolescence  Adult  Comparative Study  Delta
       Infection/BLOOD/IMMUNOLOGY/*THERAPY  English Abstract  Female  Hepatitis
       B/BLOOD/IMMUNOLOGY/*THERAPY  Hepatitis, Chronic
       Active/BLOOD/IMMUNOLOGY/*THERAPY  Human  Immunity, Cellular/DRUG EFFECTS
       Interferon Alfa, Recombinant/*ADMINISTRATION & DOSAGE
       Interferon-alpha/*ADMINISTRATION & DOSAGE  Liver
       Cirrhosis/BLOOD/IMMUNOLOGY/THERAPY  Male  Middle Age  Time Factors
       CLINICAL TRIAL  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

